MCID: GST040
MIFTS: 67

Gastric Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

MalaCards integrated aliases for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 15 17 72
Adenocarcinoma of Stomach 12 6
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3717
NCIt 50 C4004
UMLS 72 C0278701

Summaries for Gastric Adenocarcinoma

Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric papillary adenocarcinoma and adenocarcinoma, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Iron and Iron isomaltoside 1000 have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 75 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Related Diseases for Gastric Adenocarcinoma

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 586)
# Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 33.9 TP53 ERBB2
2 adenocarcinoma 31.9 TP53 SMAD4 RAF1 PTEN PIK3CA KRAS
3 gastric cancer 31.8 TP53 SMAD4 PTEN PIK3CA KRAS HOTAIR
4 peutz-jeghers syndrome 31.8 TP53 SMAD4 PTEN CTNNB1
5 familial adenomatous polyposis 31.7 TP53 SMAD4 KRAS CTNNB1
6 esophageal cancer 31.6 TP53 SMAD4 PTEN PIK3CA KRAS HRAS
7 squamous cell carcinoma 31.6 TP53 SMAD4 PTEN PIK3CA HRAS HOTAIR
8 adenoma 31.5 TP53 SMAD4 KRAS GNAS CTNNB1 BRAF
9 intrahepatic cholangiocarcinoma 31.4 TP53 KRAS FGFR2 CTNNB1
10 barrett's adenocarcinoma 31.3 TP53 KRAS ERBB2
11 exanthem 31.2 KRAS HRAS ERBB2
12 gastrointestinal stromal tumor 31.2 TP53 PTEN KRAS KIT HOTAIR BRAF
13 pancreatic cancer 31.2 TP53 SMAD4 RAF1 PIK3CA KRAS HRAS
14 ovary adenocarcinoma 31.2 TP53 PIK3CA KRAS HRAS ERBB2
15 colorectal adenocarcinoma 31.1 TP53 KRAS HRAS CTNNB1 BRAF
16 glioblastoma multiforme 31.1 TP53 PTEN PIK3CA ERBB2
17 endometrial adenocarcinoma 31.1 TP53 PTEN KRAS FGFR2 ERBB2 CTNNB1
18 breast adenocarcinoma 31.1 TP53 SMAD4 PTEN PIK3CA KRAS H19
19 small cell carcinoma 31.1 TP53 PTEN KIT
20 lipomatosis 31.0 PTEN PIK3CA FGFR1
21 glioma 31.0 TP53 PTEN PIK3CA HOTAIR H19 FGFR1
22 breast ductal carcinoma 31.0 TP53 ERBB2 CTNNB1
23 thymoma, familial 31.0 KIT HRAS
24 colorectal adenoma 30.9 TP53 KRAS HRAS CTNNB1
25 transitional cell carcinoma 30.9 TP53 PTEN HRAS ERBB2 BRAF
26 pancreas disease 30.8 TP53 SMAD4 KRAS HRAS
27 gastrointestinal system disease 30.8 TP53 KRAS KIT HRAS ERBB2 CTNNB1
28 cervical cancer 30.8 TP53 SMAD4 PTEN PIK3CA HRAS HOTAIR
29 lynch syndrome 30.8 TP53 KRAS CTNNB1 BRAF
30 nasopharyngeal carcinoma 30.8 TP53 PIK3CA NRAS HRAS HOTAIR H19
31 testicular germ cell tumor 30.7 TP53 PTEN KIT HRAS BRAF
32 cholangiocarcinoma 30.7 TP53 SMAD4 RAF1 PTEN PIK3CA KRAS
33 myeloproliferative neoplasm 30.5 KIT H19 FGFR1
34 myeloid leukemia 30.5 TP53 NRAS KIT HRAS
35 villous adenoma 30.4 KRAS GNAS BRAF
36 leukemia 30.4 TP53 RAF1 NRAS KIT HOTAIR
37 hematologic cancer 30.4 TP53 KIT HRAS FGFR1
38 thyroid cancer, nonmedullary, 2 30.3 PTEN PIK3CA NRAS HRAS BRAF
39 adrenocortical carcinoma, hereditary 30.3 TP53 PIK3CA NRAS H19 GNAS CTNNB1
40 breast cancer 30.2 TP53 SMAD4 PTEN PIK3CA KRAS KIT
41 endometrial cancer 30.1 TP53 PTEN PIK3CA KRAS KIT HRAS
42 gastrointestinal system cancer 30.1 TP53 SMAD4 PTEN PIK3CA KRAS KIT
43 leukemia, chronic myeloid 30.1 NRAS KIT HRAS HOTAIR H19 FGFR1
44 melanoma, cutaneous malignant 1 30.0 TP53 PTEN PIK3CA NRAS KIT HRAS
45 glioblastoma 30.0 TP53 PTEN PIK3CA NRAS HRAS HOTAIR
46 myeloma, multiple 30.0 TP53 NRAS KRAS KIT HRAS HOTAIR
47 bladder cancer 30.0 TP53 PCAT29 KRAS HRAS HOTAIR H19
48 sarcoma 29.9 TP53 RAF1 PIK3CA KRAS KIT HRAS
49 melanoma 29.9 TP53 PTEN NRAS HOTAIR H19 BRAF
50 large intestine cancer 29.7 TP53 SMAD4 RAF1 PTEN PIK3CA NRAS

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

GenomeRNAi Phenotypes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.03 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 11.03 KRAS
3 Decreased viability GR00221-A-1 11.03 FGFR1 HRAS KRAS PIK3CA RAF1 KIT
4 Decreased viability GR00221-A-2 11.03 FGFR1 HRAS KRAS PIK3CA RAF1
5 Decreased viability GR00221-A-3 11.03 HRAS NRAS
6 Decreased viability GR00221-A-4 11.03 PIK3CA BRAF
7 Decreased viability GR00231-A 11.03 RAF1
8 Decreased viability GR00301-A 11.03 KRAS RAF1 BRAF FGFR2 KIT
9 Decreased viability GR00342-S-1 11.03 FGFR2
10 Decreased viability GR00342-S-2 11.03 FGFR2
11 Decreased viability GR00342-S-3 11.03 FGFR2
12 Decreased viability GR00381-A-1 11.03 KRAS BRAF
13 Decreased viability GR00402-S-2 11.03 FGFR1 HRAS KRAS PIK3CA RAF1 BRAF
14 Decreased viability in esophageal squamous lineage GR00235-A 10 BRAF CTNNB1 ERBB2 GNAS HRAS KIT
15 Decreased cell migration GR00055-A-1 9.93 BRAF CTNNB1 HRAS KRAS MAP2K2 PIK3CA
16 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.91 CTNNB1 ERBB2 FGFR2 HRAS NRAS PTEN
17 Decreased substrate adherent cell growth GR00193-A-1 9.85 KIT
18 Decreased substrate adherent cell growth GR00193-A-2 9.85 KIT
19 Decreased substrate adherent cell growth GR00193-A-3 9.85 BRAF
20 Decreased substrate adherent cell growth GR00193-A-4 9.85 BRAF FGFR1 KIT
21 Increased cell death HMECs cells GR00103-A-0 9.7 CTNNB1 FGFR1 MAP2K2 PIK3CA PTEN RAF1
22 Decreased sensitivity to paclitaxel GR00112-A-0 9.4 PTEN SMAD4
23 Increased cell migration GR00055-A-3 9.35 BRAF CTNNB1 HRAS KRAS PIK3CA
24 Reduced mammosphere formation GR00396-S 9.23 BRAF GNAS H19 HRAS KRAS NRAS

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.54 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
2 cardiovascular system MP:0005385 10.53 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
3 cellular MP:0005384 10.5 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
4 endocrine/exocrine gland MP:0005379 10.5 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
5 growth/size/body region MP:0005378 10.49 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
6 homeostasis/metabolism MP:0005376 10.47 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
7 craniofacial MP:0005382 10.46 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
8 integument MP:0010771 10.45 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
9 digestive/alimentary MP:0005381 10.42 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 HRAS
10 embryo MP:0005380 10.42 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 KIT
11 mortality/aging MP:0010768 10.41 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
12 immune system MP:0005387 10.37 BRAF CTNNB1 FGFR1 FGFR2 GNAS KIT
13 hematopoietic system MP:0005397 10.35 BRAF CTNNB1 FGFR1 FGFR2 GNAS KIT
14 neoplasm MP:0002006 10.35 BRAF CTNNB1 ERBB2 FGFR2 GNAS HRAS
15 limbs/digits/tail MP:0005371 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
16 muscle MP:0005369 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
17 nervous system MP:0003631 10.3 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
18 hearing/vestibular/ear MP:0005377 10.28 BRAF CTNNB1 FGFR1 FGFR2 GNAS KIT
19 normal MP:0002873 10.28 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
20 liver/biliary system MP:0005370 10.26 BRAF CTNNB1 FGFR2 GNAS KIT KRAS
21 adipose tissue MP:0005375 10.18 BRAF FGFR2 GNAS MAP2K2 PIK3CA PTEN
22 no phenotypic analysis MP:0003012 10.17 CTNNB1 FGFR1 FGFR2 GNAS HRAS KIT
23 renal/urinary system MP:0005367 10.06 BRAF CTNNB1 FGFR1 FGFR2 GNAS HRAS
24 reproductive system MP:0005389 10 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 KIT
25 pigmentation MP:0001186 9.97 BRAF CTNNB1 FGFR2 KIT KRAS NRAS
26 respiratory system MP:0005388 9.9 BRAF CTNNB1 ERBB2 FGFR2 GNAS HRAS
27 skeleton MP:0005390 9.86 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
28 vision/eye MP:0005391 9.4 BRAF CTNNB1 FGFR1 FGFR2 KIT KRAS

Drugs & Therapeutics for Gastric Adenocarcinoma

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
2
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
3
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
4
Clarithromycin Approved Phase 4 81103-11-9 84029
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
11
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
14
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
15
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
16
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
17
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
18
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
19
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
20 Ferric Compounds Phase 4
21 Anti-Bacterial Agents Phase 4
22 Topoisomerase Inhibitors Phase 4
23 Calcium, Dietary Phase 4
24 Anti-Infective Agents Phase 4
25 Antiparasitic Agents Phase 4
26 Antiprotozoal Agents Phase 4
27 Cytochrome P-450 CYP3A Inhibitors Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Proton Pump Inhibitors Phase 4
30 Chelating Agents Phase 4
31 Antitubercular Agents Phase 4
32 Citrate Phase 4
33 diuretics Phase 4
34 Respiratory System Agents Phase 4
35 Natriuretic Agents Phase 4
36 Expectorants Phase 4
37 Anticoagulants Phase 4
38
Bismuth Phase 4 7440-69-9 16682734 105143
39 Renal Agents Phase 4
40 Anti-Infective Agents, Urinary Phase 4
41 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
42 Antimetabolites, Antineoplastic Phase 4
43 Antimetabolites Phase 4
44
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
45
Lapatinib Approved, Investigational Phase 2, Phase 3 388082-78-8, 231277-92-2 208908 9941095
46
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
47
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
48
Floxuridine Approved Phase 3 50-91-9 5790
49
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
50
Everolimus Approved Phase 3 159351-69-6 6442177 70789204

Interventional clinical trials:

(show top 50) (show all 298)
# Name Status NCT ID Phase Drugs
1 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
2 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
3 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
4 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
5 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
6 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
7 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
8 A Pharmacokinetic Study of Capecitabine in Patients Undergoing Peri-operative Chemotherapy and a Total Gastrectomy for Adenocarcinoma of the Stomach Terminated NCT00871273 Phase 4 capecitabine
9 A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy Unknown status NCT02240524 Phase 3
10 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer: A Randomized, Parallel, Controlled Study Unknown status NCT02537171 Phase 3 apatinib
11 Phase III, Randomized, Multicenter, Controlled Evaluation of S‐1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients Unknown status NCT01583361 Phase 3 Oxaliplatin+S-1;Adjuvant Oxaliplatin/S-1(SOX)
12 A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0) Unknown status NCT01283217 Phase 3 DS;SP
13 A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
14 Phase III Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection Unknown status NCT01711242 Phase 3 Capecitabine;Oxaliplatin
15 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
16 A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies Unknown status NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
17 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Completed NCT01170663 Phase 3 Placebo;Paclitaxel
18 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
19 Comparison of Efficacy of Covered Versus Uncovered Self-expandable Metallic Stents for Treatment of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Study Completed NCT01646476 Phase 3
20 Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
21 A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
22 A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma Completed NCT00411229 Phase 3 Capecitabine;Oxaliplatin
23 Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
24 A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
25 A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma Completed NCT00296335 Phase 3 Mitomycin, doxifluridine and cisplatin;Mitomycin and doxifluridine
26 A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma Completed NCT02560974 Phase 3 Capecitabine;Oxaliplatin
27 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
28 A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin Completed NCT00296322 Phase 3 cisplatin, mitomycin-C, doxifluridine
29 Phase III Randomized Controlled Trial of Adjuvant Capecitabine/Cisplatin Chemotherapy and Chemoradiation Therapy for Gastric Adenocarcinoma Completed NCT00323830 Phase 3 Capecitabine, cisplatin, Radiotherapy (+/-)
30 Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
31 Phase III Study of the Effect of Radical Gastric Surgery Versus Conventional Surgery on Recurrence and Survival in Patients With Advanced Stage Gastric Cancer. Completed NCT00260884 Phase 3
32 Phase III, Randomized, Open-label Study of Adjuvant Chemotherapy Combined With Chemoradiotherapy Versus Adujvant Chemotherapy After Standard D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma Recruiting NCT03973008 Phase 3 Adjuvant Chemotherapy
33 A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With XELOX Chemotherapy Compared to Placebo in Combination With XELOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma Recruiting NCT03802591 Phase 3 CS1001 monoclonal antibody;CS1001 placebo;Oxaliplatin;Capecitabine
34 A Multi-center, Open-label, Randomized Controlled Study of Albumin-bound Paclitaxel Plus S-1 Versus Oxaliplatin Plus S-1 (SOX) as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma Recruiting NCT03801668 Phase 3 Albumin-bound Paclitaxel plus S-1;Oxaliplatin plus S-1
35 GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study. Recruiting NCT01882933 Phase 3 HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
36 An Randomized, Multicenter, Open-label, Phase III Trial Comparing Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients With Locally Advanced Gastric Adenocarcinoma Recruiting NCT01815853 Phase 3 Neoadjuvant Chemotherapy;Adjuvant Chemotherapy
37 Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05) Recruiting NCT01917552 Phase 3 capecitabine
38 A Phase III Trial of Preoperative or Postoperative Chemoradiation Therapy for Potentially Resectable Adenocarcinoma of Stomach Cancer Recruiting NCT03223740 Phase 3
39 A Randomized Phase III Study Comparing POF (Paclitaxel/Oxaliplatin/Leucovorin/5-FU) With S-1 Plus Docetaxel as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer Recruiting NCT03788226 Phase 3 POF;Docetaxel/S-1
40 Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
41 A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) Recruiting NCT02773524 Phase 3 Regorafenib
42 Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
43 Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection (CAPOGA): A Large Multicenter Phase III Randomized Controlled Trial Recruiting NCT03817268 Phase 3 Capecitabine monotherapy
44 A Multicenter Randomized Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer Recruiting NCT02144727 Phase 3
45 A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection Recruiting NCT01534546 Phase 3 Oxaliplatin capecitabine;Oxaliplatin S-1;Oxaliplatin S-1
46 Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
47 The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer: a Multicenter, Open-label, Randomized Trial Recruiting NCT02423278 Phase 2, Phase 3 S-1+Oxaliplatin
48 A Randomized, Multicenter, Controlled, Adaptive II/III Study to Compare Neoadjuvant Chemotherapy of Docetaxel,Oxaliplatin Combined With S-1(DOS) Versus Oxaliplatin Combined With S-1(SOX)in Locally Advanced Gastric Adenocarcinoma (RESOLVE-2 Study) Active, not recruiting NCT03691454 Phase 2, Phase 3 Docetaxel;Oxaliplatin
49 A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Active, not recruiting NCT02494583 Phase 3 cisplatin;5-FU;capecitabine
50 Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer Active, not recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine

Search NIH Clinical Center for Gastric Adenocarcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Floxuridine
Mitomycin

Genetic Tests for Gastric Adenocarcinoma

Anatomical Context for Gastric Adenocarcinoma

MalaCards organs/tissues related to Gastric Adenocarcinoma:

41
Lymph Node, Liver, Bone, Lung, Colon, T Cells, Endothelial

Publications for Gastric Adenocarcinoma

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 6515)
# Title Authors PMID Year
1
CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. 9 38
19820687 2010
2
The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran. 9 38
20377133 2010
3
AFP-producing hepatoid adenocarcinoma of the stomach: a case report. 9 38
20062620 2009
4
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo. 9 38
19925030 2009
5
No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. 9 38
20057967 2009
6
Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3. 9 38
20032392 2009
7
Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. 9 38
19695681 2009
8
Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. 9 38
19369967 2009
9
Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. 9 38
20082274 2009
10
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. 9 38
19639178 2009
11
[Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth]. 9 38
20095346 2009
12
[Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]. 9 38
20017300 2009
13
Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. 9 38
19336448 2009
14
HIF-1alpha determines the metastatic potential of gastric cancer cells. 9 38
19223895 2009
15
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 9 38
18612816 2009
16
EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment. 9 38
19002606 2009
17
Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. 9 38
19688069 2009
18
Importance of gastrin in the pathogenesis and treatment of gastric tumors. 9 38
19115463 2009
19
[Protein level of transcription factors AP-1 and NF-kappaB in selected human gastrointestinal tract tumors]. 9 38
19205384 2008
20
[Vasoactive intestinal peptide expression and its clinical significance in gastric adenocarcinoma]. 9 38
19544643 2008
21
Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. 9 38
19061514 2008
22
Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas. 9 38
18807090 2008
23
Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. 9 38
18781152 2008
24
Expression of S100A4, E-cadherin, alpha- and beta-catenin in gastric adenocarcinoma. 9 38
19102422 2008
25
Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. 9 38
18570890 2008
26
Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. 9 38
18081943 2008
27
Induction of apoptosis by linoleic acid is associated with the modulation of Bcl-2 family and Fas/FasL system and activation of caspases in AGS human gastric adenocarcinoma cells. 9 38
18361731 2008
28
Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. 9 38
18262050 2008
29
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]. 9 38
18683800 2008
30
The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma. 9 38
18095267 2008
31
Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo. 9 38
17933865 2008
32
Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. 9 38
18715846 2008
33
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. 9 38
18172256 2008
34
Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. 9 38
18091326 2008
35
Expression of COX-2 in stomach carcinogenesis. 9 38
19107602 2008
36
Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. 9 38
17689858 2007
37
Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway. 9 38
17937769 2007
38
Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2. 9 38
18025257 2007
39
[Garlic oil inhibits cyclin E expression in gastric adenocarcinoma cells]. 9 38
17715037 2007
40
Effect of vasoactive intestinal peptide on gastric adenocarcinoma. 9 38
17559364 2007
41
Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. 9 38
17377791 2007
42
Genetic and epigenetic analysis of the KLF4 gene in gastric cancer. 9 38
17614846 2007
43
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. 9 38
19034345 2007
44
Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. 9 38
17552003 2007
45
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. 9 38
17230506 2007
46
Prognostic significance of maspin expression in human gastric adenocarcinoma. 9 38
17591106 2007
47
Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. 9 38
17003101 2007
48
[Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. 9 38
18172343 2007
49
Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. 9 38
17351800 2007
50
Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications. 9 38
17922051 2007

Variations for Gastric Adenocarcinoma

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6 (show top 50) (show all 361)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
2 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
3 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
4 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
5 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
6 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
7 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
8 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
9 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
10 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
11 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 19:4117551-4117551 19:4117553-4117553
12 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 18:48591918-48591918 18:51065548-51065548
13 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
14 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
15 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 17:7577556-7577556 17:7674238-7674238
16 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
17 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
18 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
19 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
20 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
21 FGFR2 NM_000141.4(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 10:123279677-123279677 10:121520163-121520163
22 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
23 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
24 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
25 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
26 NRAS NM_002524.5(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 1:115258744-115258744 1:114716123-114716123
27 RAF1 NM_002880.3(RAF1): c.770C> T (p.Ser257Leu) single nucleotide variant Pathogenic rs80338796 3:12645699-12645699 3:12604200-12604200
28 BRAF NM_004333.6(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 7:140453134-140453134 7:140753334-140753334
29 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
30 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
31 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 18:48591919-48591919 18:51065549-51065549
32 NRAS NM_002524.5(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
33 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
34 NRAS NM_002524.5(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
35 NRAS NM_002524.5(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
36 NRAS NM_002524.5(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
37 PIK3CA NM_006218.4(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 3:178927980-178927980 3:179210192-179210192
38 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
39 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
40 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
41 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
42 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
43 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 17:7577575-7577575 17:7674257-7674257
44 NRAS NM_002524.5(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
45 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
46 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
47 NRAS NM_002524.5(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
48 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 8:38274849-38274849 8:38417331-38417331
49 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
50 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305

Cosmic variations for Gastric Adenocarcinoma:

9 (show top 50) (show all 52)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6982918 YES1 skin,eye,carcinoma,NS c.851G>A p.G284E 18:743289-743289 3
2 COSM4736805 TSC1 skin,eye,carcinoma,NS c.2065C>T p.R689C 9:132903794-132903794 3
3 COSM6971614 TRAF7 skin,eye,carcinoma,NS c.349G>A p.E117K 16:2171264-2171264 3
4 COSM45444 TP53 skin,eye,carcinoma,NS c.587G>T p.R196L 17:7674944-7674944 3
5 COSM44126 TP53 skin,eye,carcinoma,NS c.507G>A p.M169I 17:7675105-7675105 3
6 COSM6937552 TP53 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
7 COSM10724 TP53 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
8 COSM43583 TP53 skin,eye,carcinoma,NS c.425C>T p.P142L 17:7675187-7675187 3
9 COSM4462891 STK40 skin,eye,carcinoma,NS c.1265C>T p.S422F 1:36341798-36341798 3
10 COSM4462893 STK40 skin,eye,carcinoma,NS c.1265C>T p.S422F 1:36341798-36341798 3
11 COSM6009093 SPEN skin,eye,carcinoma,NS c.9563C>T p.P3188L 1:15935803-15935803 3
12 COSM6982915 SOX2 skin,eye,carcinoma,NS c.237G>A p.W79* 3:181712597-181712597 3
13 COSM5538304 RNF43 skin,eye,carcinoma,NS c.866C>T p.S289F 17:58360235-58360235 3
14 COSM5468163 RAD52 skin,eye,carcinoma,NS c.779G>A p.R260Q 12:916430-916430 3
15 COSM144245 PTCH1 skin,eye,carcinoma,NS c.1585A>T p.K529* 9:95476776-95476776 3
16 COSM221754 PPP6C skin,eye,carcinoma,NS c.790C>T p.R264C 9:125149801-125149801 3
17 COSM6971613 PIK3R1 skin,eye,carcinoma,NS c.608A>G p.Y203C 5:68279707-68279707 3
18 COSM6971611 NOTCH2 skin,eye,carcinoma,NS c.4091C>T p.P1364L 1:119925725-119925725 3
19 COSM6072631 KDM5A skin,eye,carcinoma,NS c.973C>T p.P325S 12:354132-354132 3
20 COSM6982913 INPP4A skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
21 COSM6982909 IKBKE skin,eye,carcinoma,NS c.537C>A p.Y179* 1:206476359-206476359 3
22 COSM498 HRAS skin,eye,carcinoma,NS c.182A>T p.Q61L 11:533874-533874 3
23 COSM732369 FBXW7 skin,eye,carcinoma,NS c.535C>T p.R179C 4:152350091-152350091 3
24 COSM6971612 CTNNB1 skin,eye,carcinoma,NS c.1420C>T p.R474* 3:41233763-41233763 3
25 COSM13828 CDKN2A skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
26 COSM4900080 BTK skin,eye,carcinoma,NS c.262G>A p.E88K 23:101371680-101371680 3
27 COSM6971615 BRIP1 skin,eye,carcinoma,NS c.1463C>T p.P488L 17:61793607-61793607 3
28 COSM6971610 BARD1 skin,eye,carcinoma,NS c.722C>T p.S241F 2:214781152-214781152 3
29 COSM6982919 AR skin,eye,carcinoma,NS c.1883G>A p.G628E 23:67686124-67686124 3
30 COSM1432255 APC skin,eye,carcinoma,NS c.3367C>T p.Q1123* 5:112838961-112838961 3
31 COSM6971616 skin,eye,carcinoma,NS c.1463C>T p.P488L 17:61793607-61793607 3
32 COSM6982920 skin,eye,carcinoma,NS c.287G>A p.G96E 23:67686124-67686124 3
33 COSM6985419 skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
34 COSM6982912 skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
35 COSM6985418 skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
36 COSM254987 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
37 COSM6982921 skin,eye,carcinoma,NS c.1313G>A p.G438E 23:67686124-67686124 3
38 COSM6937551 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
39 COSM6971609 skin,eye,carcinoma,NS c.722C>T p.S241F 2:214781152-214781152 3
40 COSM6937553 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
41 COSM1151204 skin,eye,carcinoma,NS c.901C>T p.R301C 9:125149801-125149801 3
42 COSM1649340 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
43 COSM4462892 skin,eye,carcinoma,NS c.1280C>T p.S427F 1:36341798-36341798 3
44 COSM732370 skin,eye,carcinoma,NS c.535C>T p.R179C 4:152350091-152350091 3
45 COSM1149858 skin,eye,carcinoma,NS c.181C>T p.R61C 4:152350091-152350091 3
46 COSM732371 skin,eye,carcinoma,NS c.295C>T p.R99C 4:152350091-152350091 3
47 COSM6072630 skin,eye,carcinoma,NS c.973C>T p.P325S 12:354132-354132 3
48 COSM6937554 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
49 COSM3639486 skin,eye,carcinoma,NS c.910G>A p.E304K 7:50399977-50399977 3
50 COSM6982914 skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain C1orf88 Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain SPFH1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain ST5 Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss KIAA0179 Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma

Expression for Gastric Adenocarcinoma

Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for Gastric Adenocarcinoma

Pathways related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.39 TP53 SMAD4 RAF1 PTEN PIK3CA NRAS
2
Show member pathways
14.24 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
3
Show member pathways
14.09 TP53 RAF1 PTEN NRAS MAP2K2 KRAS
4
Show member pathways
14.07 TP53 SMAD4 RAF1 PTEN NRAS MAP2K2
5
Show member pathways
13.95 TP53 SMAD4 RAF1 NRAS MAP2K2 KRAS
6
Show member pathways
13.94 SMAD4 RAF1 PIK3CA NRAS MAP2K2 KRAS
7
Show member pathways
13.91 TP53 SMAD4 RAF1 NRAS MAP2K2 KRAS
8
Show member pathways
13.79 SMAD4 RAF1 NRAS MAP2K2 KRAS KIT
9
Show member pathways
13.76 TP53 SMAD4 RAF1 PIK3CA NRAS MAP2K2
10
Show member pathways
13.73 SMAD4 RAF1 PIK3CA NRAS MAP2K2 KRAS
11
Show member pathways
13.7 TP53 RAF1 PTEN PIK3CA NRAS KRAS
12
Show member pathways
13.65 TP53 RAF1 PTEN NRAS KRAS KIT
13
Show member pathways
13.63 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
14
Show member pathways
13.6 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
15
Show member pathways
13.57 RAF1 PTEN NRAS MAP2K2 KRAS KIT
16
Show member pathways
13.55 SMAD4 PTEN NRAS KRAS KIT HRAS
17
Show member pathways
13.52 RAF1 NRAS MAP2K2 KRAS KIT HRAS
18
Show member pathways
13.46 TP53 RAF1 PIK3CA NRAS KRAS HRAS
19
Show member pathways
13.46 TP53 RAF1 PTEN NRAS MAP2K2 KRAS
20
Show member pathways
13.32 TP53 RAF1 PTEN NRAS MAP2K2 KRAS
21
Show member pathways
13.31 RAF1 NRAS MAP2K2 KRAS KIT HRAS
22
Show member pathways
13.27 RAF1 NRAS MAP2K2 KRAS HRAS GNAS
23
Show member pathways
13.27 TP53 RAF1 NRAS MAP2K2 KRAS HRAS
24
Show member pathways
13.23 RAF1 PIK3CA NRAS MAP2K2 KRAS HRAS
25
Show member pathways
13.22 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
26
Show member pathways
13.22 TP53 SMAD4 RAF1 PTEN PIK3CA NRAS
27
Show member pathways
13.19 RAF1 KIT HRAS GNAS FGFR2 FGFR1
28
Show member pathways
13.19 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
29
Show member pathways
13.18 RAF1 PTEN NRAS MAP2K2 KRAS HRAS
30
Show member pathways
13.17 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
31
Show member pathways
13.16 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
32
Show member pathways
13.12 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
33
Show member pathways
13.11 RAF1 PIK3CA NRAS KRAS HRAS GNAS
34
Show member pathways
13.09 TP53 RAF1 NRAS MAP2K2 KRAS HRAS
35
Show member pathways
13.07 RAF1 NRAS MAP2K2 KRAS HRAS GNAS
36
Show member pathways
13.06 RAF1 PIK3CA NRAS MAP2K2 KRAS HRAS
37
Show member pathways
13.05 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
38
Show member pathways
13.04 PIK3CA NRAS KRAS HRAS FGFR2 FGFR1
39 13.04 TP53 RAF1 NRAS MAP2K2 KRAS KIT
40
Show member pathways
13.02 RAF1 PTEN PIK3CA MAP2K2 KRAS HRAS
41
Show member pathways
13 TP53 PTEN PIK3CA NRAS KRAS KIT
42
Show member pathways
12.99 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
43
Show member pathways
12.98 RAF1 PIK3CA NRAS MAP2K2 KRAS KIT
44
Show member pathways
12.95 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
45
Show member pathways
12.94 TP53 RAF1 NRAS MAP2K2 KRAS HRAS
46
Show member pathways
12.94 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
47
Show member pathways
12.93 RAF1 NRAS MAP2K2 KRAS HRAS GNAS
48 12.9 RAF1 PIK3CA NRAS MAP2K2 KRAS HRAS
49
Show member pathways
12.88 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
50
Show member pathways
12.86 TP53 PIK3CA NRAS KRAS HRAS ERBB2

GO Terms for Gastric Adenocarcinoma

Cellular components related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.97 RAF1 PTEN PIK3CA NRAS KRAS KIT
2 receptor complex GO:0043235 9.62 KIT FGFR2 FGFR1 ERBB2
3 cytoplasm GO:0005737 9.5 TP53 SMAD4 RAF1 PTEN PIK3CA MAP2K2
4 cytoplasmic side of plasma membrane GO:0009898 9.13 PTEN MAP2K2 KIT
5 cytosol GO:0005829 10.03 TP53 SMAD4 RAF1 PTEN PIK3CA MAP2K2

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.99 PTEN PIK3CA FGFR2 FGFR1
2 in utero embryonic development GO:0001701 9.98 SMAD4 FGFR2 FGFR1 CTNNB1
3 positive regulation of protein phosphorylation GO:0001934 9.97 RAF1 KRAS HRAS ERBB2
4 regulation of cell proliferation GO:0042127 9.97 SMAD4 KIT FGFR1 CTNNB1 BRAF
5 protein autophosphorylation GO:0046777 9.96 KIT FGFR2 FGFR1 ERBB2
6 positive regulation of protein kinase B signaling GO:0051897 9.96 PIK3CA KIT FGFR2 FGFR1 ERBB2
7 negative regulation of neuron apoptotic process GO:0043524 9.93 PIK3CA KRAS HRAS BRAF
8 cell differentiation GO:0030154 9.89 TP53 RAF1 CTNNB1 BRAF
9 Ras protein signal transduction GO:0007265 9.88 TP53 NRAS KRAS HRAS
10 peptidyl-tyrosine phosphorylation GO:0018108 9.88 MAP2K2 KIT FGFR2 FGFR1 ERBB2 BRAF
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 RAF1 PIK3CA BRAF
12 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.87 RAF1 NRAS KRAS HRAS
13 positive regulation of gene expression GO:0010628 9.86 TP53 PTEN KRAS KIT HRAS ERBB2
14 positive regulation of epithelial cell proliferation GO:0050679 9.85 HRAS FGFR2 ERBB2
15 visual learning GO:0008542 9.83 KRAS KIT BRAF
16 somatic stem cell population maintenance GO:0035019 9.83 SMAD4 RAF1 KIT BRAF
17 thymus development GO:0048538 9.82 RAF1 CTNNB1 BRAF
18 regulation of cell differentiation GO:0045595 9.81 RAF1 FGFR1 CTNNB1
19 midbrain development GO:0030901 9.8 FGFR2 FGFR1 CTNNB1
20 positive regulation of MAPK cascade GO:0043410 9.8 KIT HRAS FGFR2 FGFR1 ERBB2 CTNNB1
21 positive regulation of mesenchymal cell proliferation GO:0002053 9.79 FGFR2 FGFR1 CTNNB1
22 positive regulation of MAP kinase activity GO:0043406 9.77 KRAS KIT HRAS FGFR1 ERBB2
23 cell proliferation GO:0008283 9.73 TP53 SMAD4 PTEN CTNNB1
24 positive regulation of phospholipase C activity GO:0010863 9.72 KIT HRAS FGFR1
25 morphogenesis of embryonic epithelium GO:0016331 9.7 FGFR2 CTNNB1
26 branching involved in salivary gland morphogenesis GO:0060445 9.7 FGFR2 FGFR1
27 mesenchymal cell differentiation GO:0048762 9.69 FGFR2 FGFR1
28 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.69 TP53 MAP2K2
29 lung-associated mesenchyme development GO:0060484 9.69 FGFR2 FGFR1